Navigation Links
Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer

l mode of action, including its magnetic resonance imaging detectability, provides the opportunity for Xcytrin to be used in a broad range of cancers. In previously conducted randomized trials, Xcytrin combined with whole brain radiation therapy (WBRT) has been shown to prolong time to neurologic progression in patients with brain metastases from NSCLC. Xcytrin's non-overlapping toxicity makes it an appealing agent to use in combination with standard chemotherapy regimens.

The target for Xcytrin is the enzyme thioredoxin reductase, which is frequently overexpressed in lung cancer cells. This enzyme has been shown to confer to cancer cells characteristics of aggressive tumor growth and resistance to chemotherapy. First-line therapy for advanced NSCLC includes combination chemotherapy using drugs such as carboplatin, cisplatin, Gemzar(R), taxanes and others. Currently approved agents for second-line treatment of NSCLC include Alimta, Tarceva(R) and Taxotere.

About Pharmacyclics

Pharmacyclics is a pharmaceutical company developing innovative products to treat cancer and other serious diseases. The company is leveraging its small-molecule drug development expertise to build a pipeline in oncology and other diseases based on a wide range of targets, pathways and mechanisms. Its lead product, Xcytrin, has completed Phase 3 clinical trials and several ongoing Phase 1 and Phase 2 clinical trials are evaluating Xcytrin, either as a single agent or in combination with chemotherapy and/or radiation in multiple cancer types. A New Drug Application for use of Xcytrin in combination with WBRT for treatment of brain metastases from NSCLC was filed with the Food and Drug Administration in April 2007. More information about the company, its technology, and products can be found at http://www.pharmacyclics.com. In addition, more information about advocacy on behalf of Xcytrin can be found at




Page: 1 2 3 4 5

Related medicine technology :

1. Pharmacyclics Announces Promising Results From Phase 2 Clinical Trial of Xcytrin in Recurrent, Metastatic Non-Small Cell Lung Cancer
2. Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting
3. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
4. Pharmacyclics Announces Presentations on Its Novel and Selective HDAC and Brutons Tyrosine Kinase Inhibitor Compounds
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:8/3/2015)... PAUL, Minn. , Aug. 3, 2015  EnteroMedics ... using neuroblocking therapy to treat obesity, metabolic diseases and ... McDougal has been appointed to the Board of ... as a Class II Director until the 2018 annual ... Ms. McDougal has served in an executive ...
(Date:8/2/2015)... 2015 Mandatory takeover offer ... ("Dechra" or the "Company") is pleased to announce the ... Mr. Marijan Han žeković to acquire his 63.3% ... ("Genera"), a Croatian listed pharmaceutical business.   ... equivalent to €51.4 million for the entire share capital ...
(Date:7/31/2015)... -- Seeger Weiss LLP is reporting that on July 13, 2015, ... C.R. Bard, the manufacturer of Inferior vena cava (IVC) ... the agency found at two of Bard,s facilities. Bard was ... them during Inspectional Observations that occurred on November 18, 2014, ... , location and on October 6, 2014, through November ...
Breaking Medicine Technology:EnteroMedics Announces Appointment of Lori C. McDougal to the Board of Directors 2EnteroMedics Announces Appointment of Lori C. McDougal to the Board of Directors 3Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 2Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 3Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 4Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 5Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 3
(Date:8/3/2015)... ... 2015 , ... BESLER Consulting today announced the firm has ... MarketingProfs Bright Bulb B2B Awards celebrate the best marketing, communications, and creative work ... their Readmissions Analytics product was selected as one of four finalists in the ...
(Date:8/3/2015)... ... August 03, 2015 , ... Novation, the nation’s largest ... pharmacogenetic lab testing and precision medicine solutions that can help pharmacists and other ... more than 8.6 million adverse drug events are reported in the U.S. ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... fitness site and the largest online retailer of nutritional supplements, has officially ... is up for 11 awards in the following categories:, ...
(Date:8/3/2015)... ... August 03, 2015 , ... Novatus, ... contract lifecycle management solution, as well as announced the date of its next ... and ease of contract management tasks as well as enhancements to the customer ...
(Date:8/3/2015)... ... August 03, 2015 , ... AxoGen, Inc. (NASDAQ: AXGN), a leader ... present at the Wedbush Healthcare Conference on Wednesday, August 12, 2015 at 9:45am (ET) ... archived replay of the Company’s presentation may be accessed via the investor relations section ...
Breaking Medicine News(10 mins):Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 2Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 3Health News:Novatus Unveils Milestone Software Release 2Health News:AxoGen, Inc. to Present at the Wedbush Healthcare Conference 2
... Care and U.S. Soccer Federation team up to give ... a performance edge with better vision, JACKSONVILLE, Fla., March ... of ACUVUE(R) Brand Contact Lenses,today announced it is an official ... for the sport of soccer in the United,States., Under ...
... ANSYS, Inc.,(Nasdaq: ANSS ), a global innovator ... development processes, today announced it is a,sponsor of ... Carnegie Museum of,Natural History in Pittsburgh. This is ... scientifically accurate, immersive environments that are,composed of original ...
... Inc. (NYSE: HB ) (the "Company") announced today ... offer to purchase,any and all of its outstanding 4.50 ... $250 million in aggregate principal amount was,outstanding as of ... to an Offer to Purchase dated February 29, 2008 ...
... COM, VANCOUVER, March 17 /PRNewswire-FirstCall/ - ... positive interim clinical results,from its 90-day Phase ... analysis,demonstrated statistically significant efficacy for the patient ... compared to placebo. The,safety data from the ...
... Researchers will unveil a,new brain fitness training ... numerous,published studies to help people maintain health-related ... daily living tasks essential to,independence. The research ... neuroscience company, will introduce the new program, ...
... An investigational antiviral drug currently undergoing human trials ... potential to reduce muscle cell damage in Duchenne and ... led by Cincinnati Childrens Hospital Medical Center reported their ... a letter posted online March 16 by the journal ...
Cached Medicine News:Health News:U.S. Soccer Team Putting Vision in Focus for the Beijing 2008 Olympic Games 2Health News:U.S. Soccer Team Putting Vision in Focus for the Beijing 2008 Olympic Games 3Health News:ANSYS Sponsors Dinosaurs Exhibit at Carnegie Museum of Natural History 2Health News:ANSYS Sponsors Dinosaurs Exhibit at Carnegie Museum of Natural History 3Health News:Hillenbrand Industries, Inc. Announces Early Tender Results of its Pending 'Any and All' Cash Tender Offer for its 4.50 Percent Senior Notes Due 2009 2Health News:Hillenbrand Industries, Inc. Announces Early Tender Results of its Pending 'Any and All' Cash Tender Offer for its 4.50 Percent Senior Notes Due 2009 3Health News:Hillenbrand Industries, Inc. Announces Early Tender Results of its Pending 'Any and All' Cash Tender Offer for its 4.50 Percent Senior Notes Due 2009 4Health News:Hillenbrand Industries, Inc. Announces Early Tender Results of its Pending 'Any and All' Cash Tender Offer for its 4.50 Percent Senior Notes Due 2009 5Health News:Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic Advisor 2Health News:Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic Advisor 3Health News:Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic Advisor 4Health News:Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic Advisor 5Health News:Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic Advisor 6Health News:New Brain Fitness Training Promotes Health and Independence of Long Term Care Insurance Policyholders 2Health News:New Brain Fitness Training Promotes Health and Independence of Long Term Care Insurance Policyholders 3Health News:Investigational drug tested for preventing muscle fiber death in muscular dystrophy 2Health News:Investigational drug tested for preventing muscle fiber death in muscular dystrophy 3
DePuy's Shoe Boots are sealed thermoplastic boots that help provide splash protection from microorganisms, particulate matter and body fluids....
... System rede phines sharpness and efficiency ... for penetrating keratoplasty. Advanced trephine blade ... to achieve the critical fit needed for ... fully customized system enables surgeons to select ...
The MP-1 Microperimeter delivers an accurate, fully automatic assessment of the macular function. This is achieved by effectively integrating in a single instrument the objectivity of fundus imaging ...
PacePath is a comprehensive anatomic pathology software system that is the culmination of more than five years of development and testing by leading industry experts....
Medicine Products: